The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (interstitial lung disease/ILD)

Three further cases due to appear in Eur Respir J in 2016 by Haustraete et al.

Publications

Migault C, Lebrun D, Toubas O, Nguyen Y, Giltat A, Julien G, Toubas D, Lebargy F, Delmer A, Bani-Sadr F

Pulmonary adverse events related to idelalisib therapy: A single centre experience.

Journal of chemotherapy (Florence, Italy) 2018 Sep;30;318-322 — 2018 Sep — 318-322

Gosangi B, Davids M, Somarouthu B, Alessandrino F, Giardino A, Ramaiya N, Krajewski K

Review of targeted therapy in chronic lymphocytic leukemia: what a radiologist needs to know about CT interpretation.

Cancer imaging : the official publication of the International Cancer Imaging Society 2018 Apr 18;18;13 — 2018 Apr 18 — 13

Gupta A, Li HC

Idelalisib-induced pneumonitis.

BMJ case reports 2016 Aug 02;2016; — 2016 Aug 02

Haustraete E, Obert J, Diab S, Abbes S, Zini JM, Valade S, Lerolle N, Albin N, Arnulf B, Bouaziz JD, Hussenet C, Tazi A, Bergeron A

Idelalisib-related pneumonitis.

The European respiratory journal 2016 Apr;47;1280-3 — 2016 Apr — 1280-3

Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, Barrientos JC, Zelenetz AD, Kipps TJ, Flinn I, Ghia P, Eradat H, Ervin T, Lamanna N, Coiffier B, Pettitt AR, Ma S, Stilgenbauer S, Cramer P, Aiello M, Johnson DM, Miller LL, Li D, Jahn TM,

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

The New England journal of medicine 2014 Mar 13;370;997-1007 — 2014 Mar 13 — 997-1007